Lecankitug vs sonelokimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-17A/F · full Psoriasis pipeline

Lecankitug

Marketed by Livzon Pharmaceutical Group Inc. and partners

Phase 3 in Psoriasismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

sonelokimab

Developed by MoonLake Immunotherapeutics under a licence from Merck KGaA

Phase 2 in Psoriasisnanobody
Reliable signal

NCT03384745 · Phase 2 · completed

This was a well-powered, randomized, blinded, placebo-controlled trial using a validated skin-clearance measure as its primary endpoint, and every sonelokimab dose group achieved a substantially and statistically significantly higher clear/almost-clear skin rate than placebo at week 12.

Reported efficacy

Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 (Week 12, as compared to Week 0 (baseline)): Primary endpoint, IGA 0/1 at week 12: placebo 0.0%, sonelokimab 30mg 48.1% (p<0.0001), 60mg 84.6% (p<0.0001), 120mg normal load 77.4% (p<0.0001), 120mg augmented load 88.2% (p<0.0001), secukinumab 300mg (active reference) 77.4% (p<0.0001) vs placebo. (met)

Result source: NCT03384745

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLecankitugsonelokimab
PASI 75—Not posted · NCT0774647984.9% vs 90.6%vs Secukinumab120 mg · wk 12 · n 53NCT03384745
3 other results
  • 90.2% vs 90.6% 120 mg · wk 12 · n 51 · Phase 2 · secondary NCT03384745
  • 88.5% vs 90.6% 60 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
  • 65.4% vs 90.6% 30 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
PASI 90—Not posted · NCT0774647969.8% vs 64.2%vs Secukinumab120 mg · wk 12 · n 53NCT03384745
3 other results
  • 76.5% vs 64.2% 120 mg · wk 12 · n 51 · Phase 2 · secondary NCT03384745
  • 65.4% vs 64.2% 60 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
  • 36.5% vs 64.2% 30 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
PASI 100—Not posted · NCT0774647937.7% vs 28.3%vs Secukinumab120 mg · wk 12 · n 53NCT03384745
3 other results
  • 33.3% vs 28.3% 120 mg · wk 12 · n 51 · Phase 2 · secondary NCT03384745
  • 25% vs 28.3% 60 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
  • 17.3% vs 28.3% 30 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
sPGA 0/1—Not posted · NCT07746479—Not reported
DLQI, change—Not posted · NCT07746479—Not reported

PASI 75

Lecankitug
—Not posted · NCT07746479
sonelokimab
84.9% vs 90.6%vs Secukinumab120 mg · wk 12 · n 53NCT03384745
3 other results
  • 90.2% vs 90.6% 120 mg · wk 12 · n 51 · Phase 2 · secondary NCT03384745
  • 88.5% vs 90.6% 60 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
  • 65.4% vs 90.6% 30 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745

PASI 90

Lecankitug
—Not posted · NCT07746479
sonelokimab
69.8% vs 64.2%vs Secukinumab120 mg · wk 12 · n 53NCT03384745
3 other results
  • 76.5% vs 64.2% 120 mg · wk 12 · n 51 · Phase 2 · secondary NCT03384745
  • 65.4% vs 64.2% 60 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
  • 36.5% vs 64.2% 30 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745

PASI 100

Lecankitug
—Not posted · NCT07746479
sonelokimab
37.7% vs 28.3%vs Secukinumab120 mg · wk 12 · n 53NCT03384745
3 other results
  • 33.3% vs 28.3% 120 mg · wk 12 · n 51 · Phase 2 · secondary NCT03384745
  • 25% vs 28.3% 60 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745
  • 17.3% vs 28.3% 30 mg · wk 12 · n 52 · Phase 2 · secondary NCT03384745

sPGA 0/1

Lecankitug
—Not posted · NCT07746479
sonelokimab
—Not reported

DLQI, change

Lecankitug
—Not posted · NCT07746479
sonelokimab
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Lecankitug: no structured comparison results are available for Psoriasis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lecankitug: 0 of 4 rows · sonelokimab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricsonelokimab
Dropout rate
—120 mga
NCT03384745 · Phase 2
show 7 more results
—120 mg
NCT03384745 · Phase 2
5.7%120 mg
NCT03384745 · Phase 2
3.9%120 mg
NCT03384745 · Phase 2
—60 mg
NCT03384745 · Phase 2
1.9%60 mg
NCT03384745 · Phase 2
0%30 mg
NCT03384745 · Phase 2
—30 mg
NCT03384745 · Phase 2
Discontinued due to AEs
—120 mga
NCT03384745 · Phase 2
show 7 more results
—120 mg
NCT03384745 · Phase 2
1.9%120 mg
NCT03384745 · Phase 2
3.9%120 mg
NCT03384745 · Phase 2
—60 mg
NCT03384745 · Phase 2
0%60 mg
NCT03384745 · Phase 2
0%30 mg
NCT03384745 · Phase 2
—30 mg
NCT03384745 · Phase 2
Serious AEs
2%120 mga
NCT03384745 · Phase 2
show 7 more results
1.9%120 mg
NCT03384745 · Phase 2
—120 mg
NCT03384745 · Phase 2
—120 mg
NCT03384745 · Phase 2
1.9%60 mg
NCT03384745 · Phase 2
—60 mg
NCT03384745 · Phase 2
—30 mg
NCT03384745 · Phase 2
3.8%30 mg
NCT03384745 · Phase 2
Most frequent reported AEs
120 mga
nasopharyngitis 7.8% (placebo 7.7%)
pruritus 7.8% (placebo 3.8%)
oral candidiasis 5.9% (placebo 0%)
NCT03384745 · Phase 2
show 3 more results
120 mg
nasopharyngitis 17% (placebo 7.7%)
headache 5.7% (placebo 1.9%)
pruritus 5.7% (placebo 3.8%)
NCT03384745 · Phase 2
60 mg
nasopharyngitis 21.2% (placebo 7.7%)
pruritus 7.7% (placebo 3.8%)
headache 5.8% (placebo 1.9%)
NCT03384745 · Phase 2
30 mg
nasopharyngitis 7.7% (placebo 7.7%)
arthralgia 5.8% (placebo 1.9%)
hypertension 5.8% (placebo 3.8%)
NCT03384745 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

sonelokimab

IGA 0/1 77.4% (n=53) vs 0% (n=52) placebo @ 12wk120 mg
responder rate · % of participants
NCT03384745 · Phase 2 · converted to % from 41 Participants as posted
show 3 more results
88.2% (n=51) vs 0% (n=52) placebo @ 12wk*120 mg
NCT03384745 · Phase 2 · converted to % from 45 Participants as posted
84.6% (n=52) vs 0% (n=52) placebo @ 12wk*60 mg
NCT03384745 · Phase 2 · converted to % from 44 Participants as posted
48.1% (n=52) vs 0% (n=52) placebo @ 12wk*30 mg
NCT03384745 · Phase 2 · converted to % from 25 Participants as posted
PASI 100 37.7% (n=53) vs 28.3% (n=53) Secukinumab @ 12wk120 mg
responder rate · % of participants
NCT03384745 · Phase 2 · converted to % from 20 Participants as posted
show 3 more results
33.3% (n=51) vs 28.3% (n=53) Secukinumab @ 12wk*120 mg
NCT03384745 · Phase 2 · converted to % from 17 Participants as posted
25% (n=52) vs 28.3% (n=53) Secukinumab @ 12wk*60 mg
NCT03384745 · Phase 2 · converted to % from 13 Participants as posted
17.3% (n=52) vs 28.3% (n=53) Secukinumab @ 12wk*30 mg
NCT03384745 · Phase 2 · converted to % from 9 Participants as posted
PASI 90 69.8% (n=53) vs 64.2% (n=53) Secukinumab @ 12wk120 mg
responder rate · % of participants
NCT03384745 · Phase 2 · converted to % from 37 Participants as posted
show 3 more results
76.5% (n=51) vs 64.2% (n=53) Secukinumab @ 12wk*120 mg
NCT03384745 · Phase 2 · converted to % from 39 Participants as posted
65.4% (n=52) vs 64.2% (n=53) Secukinumab @ 12wk*60 mg
NCT03384745 · Phase 2 · converted to % from 34 Participants as posted
36.5% (n=52) vs 64.2% (n=53) Secukinumab @ 12wk*30 mg
NCT03384745 · Phase 2 · converted to % from 19 Participants as posted
PASI 75 84.9% (n=53) vs 90.6% (n=53) Secukinumab @ 12wk120 mg
responder rate · % of participants
NCT03384745 · Phase 2 · converted to % from 45 Participants as posted
show 3 more results
90.2% (n=51) vs 90.6% (n=53) Secukinumab @ 12wk*120 mg
NCT03384745 · Phase 2 · converted to % from 46 Participants as posted
88.5% (n=52) vs 90.6% (n=53) Secukinumab @ 12wk*60 mg
NCT03384745 · Phase 2 · converted to % from 46 Participants as posted
65.4% (n=52) vs 90.6% (n=53) Secukinumab @ 12wk*30 mg
NCT03384745 · Phase 2 · converted to % from 34 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lecankitug's landscape · sonelokimab's landscape